drugset / Trial / NCT01442610
Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease
Phase 4
Completed
30 enrolled
Technical University Dresden
Teva Branded Pharmaceutical Products R&D, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
As the MAO-B inhibitor rasagiline is able to improve motor skills it might have positive effects on sleep disruption by reducing nocturnal akinesia. As it was reported to cause only minor sleep disruption in PD Patients, it might be able to improve sleep architecture. The investigators thus study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and PDSS-2. Secondary measures are other sleep variables measured by PSG, sleep quality and daytime sleepiness assessed by standardized scales as well as cognitive function, depression and QoL index.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-03
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rasagiline | Small molecule | 1 mg | — |